Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Operating Expenses (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Operating Expenses for 16 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 119.55% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, up 39.46% year-over-year, with the annual reading at $2.9 million for FY2025, 39.48% up from the prior year.
  • Operating Expenses hit $1.2 million in Q4 2025 for Guided Therapeutics, up from $520000.0 in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $1.5 million in Q2 2023 to a low of $363000.0 in Q1 2024.
  • Historically, Operating Expenses has averaged $706850.0 across 5 years, with a median of $591000.0 in 2021.
  • Biggest five-year swings in Operating Expenses: skyrocketed 240.08% in 2021 and later crashed 57.59% in 2024.
  • Year by year, Operating Expenses stood at $476000.0 in 2021, then skyrocketed by 82.56% to $869000.0 in 2022, then tumbled by 42.35% to $501000.0 in 2023, then increased by 6.19% to $532000.0 in 2024, then soared by 119.55% to $1.2 million in 2025.
  • Business Quant data shows Operating Expenses for GTHP at $1.2 million in Q4 2025, $520000.0 in Q3 2025, and $842000.0 in Q2 2025.